Ro, a direct-to-consumer health and wellness company, has announced a partnership with Eli Lilly to provide discounted single-dose vials of the weight-loss medication Zepbound. Through this collaboration, Ro will utilize LillyDirect, Eli Lilly’s self-pay pharmacy channel, to deliver Zepbound to eligible patients with on-label prescriptions provided by Ro’s healthcare providers.
The partnership aims to make a more affordable version of the obesity treatment accessible to clinically eligible patients at self-pay prices. According to Ro, this new offering integrates diagnosis, treatment, and delivery into a seamless patient journey within a single application. This approach enables continuous care coordination, disease management, and personalized care plans tailored to each individual’s needs.
The single-dose vials of Zepbound are available in 2.5 mg and 5 mg doses, priced at $399 and $549 per month respectively for cash-paying customers without insurance coverage. This pricing aligns with Eli Lilly’s initiative launched in August, offering Zepbound doses through its LillyDirect platform at discounts exceeding 50% compared to the list price of other GLP-1 obesity treatments.
Ro introduced its weight-loss program in January 2023, giving members access to GLP-1 medications alongside personalized care plans, diagnostic testing with at-home sample collection, and one-on-one coaching from nurses. In May, Ro also launched an online supply tracker for GLP-1 medications, providing real-time updates on availability as an interactive tool for patients.
Zepbound was initially offered as a self-pay-only treatment for diabetes patients through LillyDirect. By integrating its offerings with Ro’s platform, patients can now access Zepbound without ever leaving the Ro app or their homes.
Ro Partners With Eli Lilly to Offer Zepbound, a Weight-Loss Medication, in Single-Dose Vials
-
